Document is current
Any future updates will be listed below
-
Authors
Poleur, Margaux
Ulinici, Ana
Daron, Aurore
Schneider, Olivier
Farra, Fabian Dal
Demonceau, Marie
Annoussamy, Mélanie
Vissière, David
Eggenspieler, Damien
Servais, Laurent https://orcid.org/0000-0001-9270-4061
-
Funding
Funding for this research was provided by:
Action Duchenne
- License Information
-
More Information
Article History
Received: 28 January 2021
Accepted: 11 July 2021
First Online: 19 July 2021
Declarations
:
: The study was approved by the ethics committees of the Citadelle Regional Hospital Centre in Liège (Belgian N°: B412201731844), and the experiment was conducted in accordance with the good clinical practice and with the Declaration of Helsinki (2013). Prior to their inclusion in the study, all participants (and/or their legal guardians) gave their full written informed consent.
: Not applicable.
: Academic authors declare no competing interests. Melanie Annoussamy and Damien Eggenspieler are employed by Synsav, the medium-sized enterprise responsible for ActiMyo® development. David Vissière is the CEO, founder and main shareholder of Sysnav.
